Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering
February 27, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
February 24, 2023 07:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder
February 21, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe CHARLOTTESVILLE, Va., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Adial...
Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
February 01, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley ...
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 08:30 ET
|
Adial Pharmaceuticals, Inc
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to...
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain
September 26, 2022 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial...
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
September 06, 2022 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial...
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer
August 22, 2022 16:30 ET
|
Adial Pharmaceuticals, Inc
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow ...
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 16, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies ...
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
July 20, 2022 07:00 ET
|
Adial Pharmaceuticals, Inc
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline...